DxS Extends EGFR Licensing Deal with Genzyme Genetics | GenomeWeb
NEW YORK (GenomeWeb News) – DxS today said that it has expanded its licensing deal with Genzyme Genetics covering the epidermal growth factor receptor gene.
 
The license gives Manchester, UK-based DxS rights to develop and sell diagnostic and research products that detect mutations in the EGFR gene for non-small cell lung cancer in the US and Canada. The deal builds on an agreement inked earlier this year that gave DxS similar rights to EGFR worldwide, except for North America and Hong Kong.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.